Onyx at High Seen Poised to Reap 40% More in Any Takeover

Onyx Pharmaceuticals Inc., which surged to a record last week, is poised to hand shareholders 40 percent more after a regulatory panel’s support for a cancer treatment heightened its allure as a takeover target.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.